Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434733
Status:
COMPLETED
Last Update Posted:
2008-04-24
First Post:
2007-02-12
Brief Title:
Immunogenicity Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase III Randomized Controlled Observer-Blind Multicenter Study to Evaluate the Immunogenicity Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the immunogenicity safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent interpandemic FLUAD each administered 3 weeks apart
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-005428-18 | None | None | None |